Abstract
The occurrence of orthosteric and allosteric binding sites is a characteristic common feature of several acetylcholine- binding proteins, like acetylcholinesterase or the nicotinic and muscarinic acetylcholine receptors. These proteins are involved in a number of neurological disorders, such as Alzheimers disease, and represent important therapeutic targets for the development of heterodimeric ligands addressing both of their binding sites. Among the pharmacophores, which have been combined in such heterodimers, the tetrahydroacridine derivative tacrine has attracted particular interest. This review discusses the chemistry behind the linker connection of tacrine to other pharmacophores and summarizes the types of linkers established to date. Especially, the development of a hydrazide linker for tacrine-derived heterodimers is highlighted by applications in the inhibition of cholinesterases, the bivalent binding to nicotinic and muscarinic acetylcholine receptors, as well as the histochemical imaging of acetylcholinesterase and amyloid-β.
Keywords: Acetylcholinesterase, allosteric/orthosteric ligands, amyloid-β, bivalent ligands, butyrylcholinesterase, heterodimers, hydrazides, linker, muscarinic acetylcholine receptors, nicotinic acetylcholine receptors, Cholinergic transmission, cholinergic synapses, hydrolyticdeacylation, synthetic inhibitors, neurofibrillary tangles
Current Topics in Medicinal Chemistry
Title: A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins
Volume: 11 Issue: 22
Author(s): Paul W. Elsinghorst, Wolfgang Hartig, Daniela Gundisch, Klaus Mohr, Christian Trankle and Michael Gutschow
Affiliation:
Keywords: Acetylcholinesterase, allosteric/orthosteric ligands, amyloid-β, bivalent ligands, butyrylcholinesterase, heterodimers, hydrazides, linker, muscarinic acetylcholine receptors, nicotinic acetylcholine receptors, Cholinergic transmission, cholinergic synapses, hydrolyticdeacylation, synthetic inhibitors, neurofibrillary tangles
Abstract: The occurrence of orthosteric and allosteric binding sites is a characteristic common feature of several acetylcholine- binding proteins, like acetylcholinesterase or the nicotinic and muscarinic acetylcholine receptors. These proteins are involved in a number of neurological disorders, such as Alzheimers disease, and represent important therapeutic targets for the development of heterodimeric ligands addressing both of their binding sites. Among the pharmacophores, which have been combined in such heterodimers, the tetrahydroacridine derivative tacrine has attracted particular interest. This review discusses the chemistry behind the linker connection of tacrine to other pharmacophores and summarizes the types of linkers established to date. Especially, the development of a hydrazide linker for tacrine-derived heterodimers is highlighted by applications in the inhibition of cholinesterases, the bivalent binding to nicotinic and muscarinic acetylcholine receptors, as well as the histochemical imaging of acetylcholinesterase and amyloid-β.
Export Options
About this article
Cite this article as:
W. Elsinghorst Paul, Hartig Wolfgang, Gundisch Daniela, Mohr Klaus, Trankle Christian and Gutschow Michael, A Hydrazide Linker Strategy for Heterobivalent Compounds as Ortho- and Allosteric Ligands of Acetylcholine-Binding Proteins, Current Topics in Medicinal Chemistry 2011; 11 (22) . https://dx.doi.org/10.2174/156802611798184427
DOI https://dx.doi.org/10.2174/156802611798184427 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Microarray RNA/DNA in Different Stem Cell Lines
Current Pharmaceutical Biotechnology Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Amalgamation of Stem Cells with Nanotechnology: A Unique Therapeutic Approach
Current Stem Cell Research & Therapy β-amyloid and Oxidative Stress: Perspectives in Drug Development
Current Pharmaceutical Design Sirtuins as Possible Targets in Neurodegenerative Diseases
Current Drug Targets Targeting the Eph System with Peptides and Peptide Conjugates
Current Drug Targets Brain-Derived Neurotrophic Factor (BDNF) has Proliferative Effects on Neural Stem Cells through the Truncated TRK-B Receptor, MAP Kinase, AKT, and STAT-3 Signaling Pathways
Current Neurovascular Research Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Synthetic Applications of the Nenitzescu Reaction to Biologically Active 5-Hydroxyindoles
Current Organic Chemistry Recent Advances in the Medicinal Chemistry of Aurones
Current Medicinal Chemistry Role of Fibroblast Growth Factor Receptors in Astrocytic Stem Cells
Current Signal Transduction Therapy The Many Neuroprogressive Actions of Tryptophan Catabolites (TRYCATs) that may be Associated with the Pathophysiology of Neuro-Immune Disorders
Current Pharmaceutical Design Ubiquitin-Protein Ligases - Novel Therapeutic Targets?
Current Protein & Peptide Science Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Tau in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Role of Sirtuins and Calorie Restriction in Neuroprotection: Implications in Alzheimers and Parkinsons Diseases
Current Pharmaceutical Design Editorial [Hot Topic: Bringing Drugs Into the Injured Brain and Keeping Them There (Executive Guest Editors: Dirk M. Hermann and Pauline Patak)]
Current Pharmaceutical Design Prion Protein Misfolding
Current Molecular Medicine Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research